Biologic

Results: 1831



#Item
1Commited to Biologic Innovation

Commited to Biologic Innovation

Add to Reading List

Source URL: www.abbvie.ca

Language: English - Date: 2018-07-18 09:23:00
    2Special Authorization Criteria for Biologic Drugs For each disease category specified below, the biologic drugs listed will only be considered for reimbursement if the patient has failed an adequate trial or experienced

    Special Authorization Criteria for Biologic Drugs For each disease category specified below, the biologic drugs listed will only be considered for reimbursement if the patient has failed an adequate trial or experienced

    Add to Reading List

    Source URL: www.writerscoalition.ca

    Language: English - Date: 2018-02-13 17:23:55
      3ASX ANNOUNCEMENT 10 February 2014 Cynata Partners With Leading Biologic Product Manufacturer Cynata Therapeutics Ltd (ASX:CYP), announced today that it has signed a manufacturing agreement

      ASX ANNOUNCEMENT 10 February 2014 Cynata Partners With Leading Biologic Product Manufacturer Cynata Therapeutics Ltd (ASX:CYP), announced today that it has signed a manufacturing agreement

      Add to Reading List

      Source URL: cynata.com

      - Date: 2016-03-08 18:52:12
        4Stakeholder Meeting on PDUFA VI Reauthorization September 28, 2015, 1:30 PM – 3.05 PM FDA White Oak Campus, Silver Spring, MD Purpose To discuss the current status of the human drug and biologic review programs, review

        Stakeholder Meeting on PDUFA VI Reauthorization September 28, 2015, 1:30 PM – 3.05 PM FDA White Oak Campus, Silver Spring, MD Purpose To discuss the current status of the human drug and biologic review programs, review

        Add to Reading List

        Source URL: www.fda.gov

          5Council Report AVMA Council on Biologic and Therapeutic Agents’ report on cat and dog vaccines Donald J. Klingborg, DVM; David R. Hustead, DVM; Elizabeth A. Curry-Galvin, DVM; Nigel R. Gumley, DVM, DABVP; Steven C. Hen

          Council Report AVMA Council on Biologic and Therapeutic Agents’ report on cat and dog vaccines Donald J. Klingborg, DVM; David R. Hustead, DVM; Elizabeth A. Curry-Galvin, DVM; Nigel R. Gumley, DVM, DABVP; Steven C. Hen

          Add to Reading List

          Source URL: www.avma.org

          - Date: 2012-05-14 07:52:42
            6Site-specific Chemoenzymatic Glycosylation of Peptides For many eukaryotic proteins, processing by post-translational modifications such as glycosylation is a critical step for correct folding and achievement of biologic

            Site-specific Chemoenzymatic Glycosylation of Peptides For many eukaryotic proteins, processing by post-translational modifications such as glycosylation is a critical step for correct folding and achievement of biologic

            Add to Reading List

            Source URL: techtransfer.univie.ac.at

            Language: English - Date: 2015-03-26 09:05:54
            7IMPORTANT DRUG WARNING Dear Healthcare Provider, The purpose of this letter is to inform you of updated important safety information about XIAFLEX® (collagenase clostridium histolyticum), a biologic medication indicate

            IMPORTANT DRUG WARNING Dear Healthcare Provider, The purpose of this letter is to inform you of updated important safety information about XIAFLEX® (collagenase clostridium histolyticum), a biologic medication indicate

            Add to Reading List

            Source URL: www.xiaflexrems.com

            Language: English - Date: 2015-01-08 08:27:00
            8≤ Benefits Bulletin≥ April 2013 In This Issue Changes to the Biologic Landscape: The Entry of

            ≤ Benefits Bulletin≥ April 2013 In This Issue Changes to the Biologic Landscape: The Entry of

            Add to Reading List

            Source URL: www.bayneswhite.com

            Language: English - Date: 2013-05-10 15:24:41
            9Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor α antibody, in a phase I study of patients with mild asthma

            Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor α antibody, in a phase I study of patients with mild asthma

            Add to Reading List

            Source URL: web.emmes.com

            Language: English - Date: 2013-01-10 14:05:36
            10Microsoft Word - Savient Resubmits Biologics License Application for KRYSTEXXAdoc

            Microsoft Word - Savient Resubmits Biologics License Application for KRYSTEXXAdoc

            Add to Reading List

            Source URL: www.mvpharm.com

            Language: English - Date: 2016-07-11 16:59:56